Published in Medicine and Law Weekly, July 2nd, 2010
Although at least one analyst has a target price of $30.00 per share, TLCR shareholders will receive only $26.16 in the proposed partial cash and stock deal. Regrettably, the offer price is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly